Study wrapper · #1285
IDE-mediated GLP-1 degradation as the basis for designing long-acting and CNS-stable GLP-1 receptor agonists.
Editor's note
A mechanistic study in Science Advances, run in mice and in tissue secretomes, that identifies a previously undescribed route of GLP-1 breakdown and then uses it as a design target. The compound tested is a D-amino-acid variant, not the semaglutide available to patients, so the results speak to future drug design rather than to how current dosing behaves in people. The findings are internally consistent, including an enzyme-knockdown control and direct brain injection, but they remain entirely preclinical.
Plain-language abstract
Researchers found that insulin-degrading enzyme breaks down the natural gut hormone GLP-1, including inside the brain, at two specific sites. By swapping in mirror-image amino acids at those sites they built a modified version of semaglutide that resisted the breakdown. In mice, the redesigned molecule stayed in the blood longer and lowered glucose for longer than the standard version.